Denali Therapeutics Inc.
DNLI
$20.57
-$0.13-0.63%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -21.23% | -16.67% | -14.15% | -230.75% | -191.12% |
| Total Depreciation and Amortization | 64.72% | 1,999.85% | 1,916.05% | 967.16% | 1.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 72.90% | 57.05% | 48.06% | 32.94% | -28.07% |
| Change in Net Operating Assets | -99.12% | -53.50% | 287.60% | 103.30% | 105.84% |
| Cash from Operations | -18.67% | -9.69% | 10.55% | 11.45% | 2.88% |
| Capital Expenditure | 40.28% | -0.11% | -63.11% | -53.13% | -22.98% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 463.49% | 340.07% | 372.03% | 506.65% | -127.78% |
| Cash from Investing | 387.62% | 316.44% | 344.96% | 444.70% | -135.60% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 74.74% | 31.40% | -- | -- | -- |
| Issuance of Common Stock | 79.01% | -98.19% | -97.23% | -96.72% | 2,801.92% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -151,634.17% | 100.00% | 100.00% | 100.00% | -- |
| Cash from Financing | -60.93% | -101.44% | -104.84% | -103.82% | 2,617.76% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -33.35% | 103.24% | 218.79% | 71.99% | 152.67% |